Swiss Biotech Report 2018
The unbridled success of the Swiss Biotech industry continues apace
The Swiss biotech industry has reached record figures for 2017 in financing, infrastructure investment, and exports. This shows that confidence in its ability to create value and innovate remains unshaken. The most prominent example is the acquisition of Actelion by Johnson & Johnson, which, at almost USD 30 billion, was the largest stock exchange transaction worldwide within the life sciences industry over the past year.
The unbridled success of the Swiss Biotech industry continues apace - May 3, 2018 Ungebremster Höhenflug der Schweizer Biotech-Branche - 3. Mai 2018 Le secteur des biotechnologies a poursuivi son irrésistible ascension - le 3 mai 2018 Swiss Biotech Report presentation - May 3, 2018